Navigation Links
Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding
Date:1/29/2008

OXFORD, England, January 29 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, announced today that it has successfully raised GBP11 million ($21.8 million) in an oversubscribed second round funding. The investment syndicate includes new investors Goldman Sachs and Invesco Perpetual, as well as existing investors, including Imperial Innovations and Lansdowne Partners.

"Completing this financing is a testament to the potential of Circassia's business, management and technology," said Steve Harris, Circassia's CEO. "We have made good progress advancing our anti-allergy products during the last year, and successfully completing this funding, particularly in the current challenging market conditions, is a strong vote of confidence from a syndicate of world-class investors."

Circassia, whose immune control technologies target allergies and organ rejection, completed an initial investment round of GBP6 million ($11.8 million) in January 2007. During the last year the company has finalised preparations to complete the phase II clinical testing programme for its lead product against cat dander allergy, and finalised the acquisition of its ToleroTrans organ anti-rejection technology. Following this second investment round, Circassia has increased its current cash balance to GBP15 million ($29.8 million), and plans to utilise the funds both to progress its clinical development programmes and to acquire additional technologies that fit its specialty business model.

Circassia's products have the potential to address significant market opportunities. Currently, over 150 million people suffer from allergic rhinitis in the US and Europe, and existing treatments either provide symptomatic relief only or require lengthy specialist physician supervision over a period of many months due to potential serious, even life-threatening, adverse reactions. In contrast, Circassia's technology uses small sections of the allergen molecules responsible for causing allergies (termed T-cell epitopes) to rapidly desensitize sufferers, while minimizing the potential for adverse reactions. The company's ToleroTrans technology uses a similar scientific approach designed to desensitize transplant patients and thereby reduce the risk of organ rejection.

About Circassia

Circassia is a specialty biopharmaceutical company focused on developing medicines designed to control immune system responses. The company has a highly experienced management team with a proven track record in product development and commercialisation, and having successfully completed two substantial fundraising rounds is backed by a syndicate of world-class venture capital and institutional investors.

Circassia's lead products target allergies utilising the company's proprietary T-cell epitope desensitization technology, which was originally developed at Imperial College London. The company is also developing its ToleroTrans organ anti-rejection technology, which uses a similar approach to down-regulate immune responses in transplant patients. Circassia has a number of ongoing development programmes, with the most advanced against cat dander allergy having successfully completed a phase II clinical trial.

For more information please visit http://www.circassia.co.uk.


'/>"/>
SOURCE Circassia Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Primera Biosystems Raises $21 Million in Series B Private Round
2. Cellectar, Inc. Raises $13 Million in Private Offering
3. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
4. Anesiva Raises $45 Million in Common Stock Offering
5. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
6. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
9. VisEn Medical Raises $7 Million in Series B Financing
10. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
11. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... NEW YORK , May 2, 2016 ... company announces that its technology partner Mannin Research Inc. ... and Ophthalmology (ARVO), which takes place from May 1-5, ... Research executives will be meeting with its vendors and ... further explore business development goals and other collaborative opportunities ...
(Date:4/29/2016)... ... April 30, 2016 , ... The MIT bioLogic design ... the bioLogic team explored how bacterial properties can be applied to fabric and formed ... bacteria, which move in response to humidity change. The team harvested Natto cells and ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... the necessary fundamentals to transform technology into a viable company, CereScan’s CEO, John ... Mr. Kelley, a recognized leader and mentor in the Denver area business ...
(Date:4/28/2016)... 2016 The report "Cryocooler Market ... Service (Technical Support, Product Repairs & Refurbishment, Preventive Maintenance, ... to 2022", published by MarketsandMarkets, the global market is ... at a CAGR of 7.29% between 2016 and 2022. ... 94 Figures spread through 159 Pages and in-depth TOC ...
Breaking Biology Technology:
(Date:3/15/2016)... 15, 2016 Yissum Research Development Company ... company of the Hebrew University, announced today the formation ... technology of various human biological indicators. Neteera Technologies has ... from private investors. ... detection of electromagnetic emissions from sweat ducts, enables reliable ...
(Date:3/14/2016)... March 14, 2016 http://www.apimages.com ... --> - Renvoi : image disponible via ... --> --> DERMALOG, le ... de nouveaux lecteurs d,empreintes digitales pour l,enregistrement des ... sera utilisé pour produire des cartes d,identité aux ...
(Date:3/11/2016)... India , March 11, 2016 ... a new market research report "Image Recognition Market by ... Application (Marketing and Advertising), by Deployment Type (On-Premises and ... Forecast To 2022", published by MarketsandMarkets, the global market ... 2015 to USD 29.98 Billion by 2020, at a ...
Breaking Biology News(10 mins):